VIA
PTCT icon

Vident Investment Advisory’s PTC Therapeutics PTCT Stock Holding History

Vident Investment Advisory’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,863
Closed -$206K – 1218
2021
Q2 		$206K Buy
+4,863
New +$208K 0.01% 1049

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vident Investment Advisory's PTCT Position: Q3 2021 in Review

Vident Investment Advisory sold out of PTC Therapeutics (PTCT) in Q3 2021, closing a stake of 4,863 shares — an estimated $206K sold.

Vident Investment Advisory first reported a position in PTCT in Q2 2021 and held it in 1 quarter. The position peaked at $206K in Q2 2021. 182 funds tracked by Wall St. Rank hold PTCT as of Q3 2021.

  • Vident Investment Advisory reported no remaining PTC Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Vident Investment Advisory sold 4,863 PTC Therapeutics shares in Q3 2021, an estimated $206K.
  • Vident Investment Advisory first reported a position in PTC Therapeutics in Q2 2021 and held it in 1 quarter.
  • Vident Investment Advisory's PTC Therapeutics position peaked at $206K in Q2 2021.
  • 182 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2021.

Based on Vident Investment Advisory's 13F filing for Q3 2021, filed 12 Nov 2021.